AxisPharm provides high purity PROTAC PEG reagents (linkers) with various active groups, such as azide, acid, amine, etc.
The design of Proteolysis Targeting Chimera (PROTACs) is a powerful small molecule approach for inducing protein degradation for anticancer therapy. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. To further empower the PROTAC study, AxisPharm are developing a series of PROTAC linker to accelerate our customers’ R&D effort.
- Thalidomide-O-PEG-NHS ester
- Thalidomide-O-PEG-t-butyl ester
- VHL Ligand 1
- (S,R. S)-AHPC-PEG-acid
- (S,R. S)-AHPC-PEG-amine
- (S,R. S)-AHPC-PEG-Azide